The following co-cited articles involved an open-label trial of dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) combination therapy in BRAF V600E-mutated anaplastic thyroid cancer (23). Here, BRAF is linked to thyroid gland undifferentiated (anaplastic) carcinoma.